Clinical Characteristics, Diagnosis, and Therapeutics of COVID-19: A Review

Abstract

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that suddenly emerged at the end of December 2019 and caused coronavirus disease 2019 (COVID-19) continues to afflict humanity, not only seriously affecting healthcare systems but also leading to global social and economic imbalances. As of August 2022, there were approximately 580 million confirmed cases of COVID-19 and approximately 6.4 million confirmed deaths due to this disease. The data are sufficient to highlight the seriousness of SARS-CoV-2 infection. Although most patients with COVID-19 present primarily with respiratory symptoms, an increasing number of extrapulmonary systemic symptoms and manifestations have been associated with COVID-19. Since the outbreak of COVID-19, much has been learned about the disease and its causative agent. Therefore, great effort has been aimed at developing treatments and drug interventions to treat and reduce the incidence of COVID-19. In this narrative review, we provide a brief overview of the epidemiology, mechanisms, clinical manifestations, diagnosis, and therapeutics of COVID-19.

Keywords

coronavirus disease 2019 / severe acute respiratory syndrome coronavirus 2 / mechanism / clinical manifestations / diagnosis / therapeutics

References

[1] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol, 2020, 5(4): 536-544

[2] GralinskiLE, MenacheryVD. Return of the Coronavirus: 2019-nCoV. Viruses, 2020, 12(2): 135

[3] WiersingaWJ, RhodesA, ChengAC, et al.. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA, 2020, 324(8): 782-793

[4] WangC, HorbyPW, HaydenFG, et al.. A novel coronavirus outbreak of global health concern. Lancet, 2020, 395(10223): 470-473

[5] ChanJF, YuanS, KokKH, et al.. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020, 395(10223): 514-523

[6] RimmerA. Covid-19: doctors in final trimester of pregnancy should avoid direct patient contact. BMJ, 2020, 368: 1173

[7] ActerT, UddinN, DasJ, et al.. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Sci Total Environ, 2020, 730: 138996

[8] RehmanSU, ShafiqueL, IhsanA, et al.. Evolutionary Trajectory for the Emergence of Novel Coronavirus SARS-CoV-2. Pathogens, 2020, 9(3): 240

[9] CuiJ, LiF, ShiZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol, 2019, 17(3): 181-192

[10] MittalA, ManjunathK, RanjanRK, et al.. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. PLoS Pathog, 2020, 16(8): e1008762

[11] MollaeiHR, AfsharAA, Kalantar-NeyestanakiD, et al.. Comparison of five primer sets from different genome region of COVID-19 for detection of virus infection by conventional RT-PCR. Iran J Microbiol, 2020, 12(3): 185-193

[12] Sanders W, Fritch EJ, Madden EA, et al. Comparative analysis of coronavirus genomic RNA structure reveals conservation in SARS-like coronaviruses. bioRxiv, 2020:2020.06.15.153197

[13] SchoemanD, FieldingBC. Coronavirus envelope protein: current knowledge. Virol J, 2019, 16(1): 69

[14] ChenY, LiuQ, GuoD. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol, 2020, 92(10): 2249

[15] MercurioI, TragniV, BustoF, et al.. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. Cell Mol Life Sci, 2021, 78(4): 1501-1522

[16] MahmoudIS, JarrarYB, AlshaerW, et al.. SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention. Biochimie, 2020, 175: 93-98

[17] ChenY, GuoY, PanY, et al.. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun, 2020, 525(1): 135-140

[18] GussowAB, AuslanderN, FaureG, et al.. Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses. Proc Natl Acad Sci USA, 2020, 117(26): 15193-15199

[19] KimD, LeeJY, YangJS, et al.. The Architecture of SARS-CoV-2 Transcrrptome. Cell, 2020, 181(4): 914-921.e10

[20] WuJ, LiJ, ZhuG, et al.. Clinical Features of Maintenance Hemodialysis Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Clin J Am Soc Nephrol, 2020, 15(8): 1139-1145

[21] HuangC, WangY, LiX, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506

[22] HarcourtJ, TaminA, LuX, et al.. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States. Emerg Infect Dis, 2020, 26(6): 1266-1273

[23] WangW, TangJ, WeiF. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol, 2020, 92(4): 441-447

[24] YeZ, ZhangY, WangY, et al.. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol, 2020, 30(8): 4381-4389

[25] ImaiK, TabataS, IkedaM, et al.. Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19. J Clin Virol, 2020, 128: 104393

[26] YangK. What Do We Know About Remdesivir Drug Interactions?. Clin Transl Sci, 2020, 13(5): 842-844

[27] UdugamaB, KadhiresanP, KozlowskiHN, et al.. Diagnosing COVID-19: The Disease and Tools for Detection. ACS Nano, 2020, 14(4): 3822-3835

[28] LiZ, YiY, LuoX, et al.. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol, 2020, 92(9): 1518-1524

[29] AsciertoPA, FoxBA, UrbaWJ, et al.. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer, 2020, 8(1): e000878

[30] TurnerAJ, HiscoxJA, HooperNM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci, 2004, 25(6): 291-294

[31] KangY, ChenT, MuiD, et al.. Cardiovascular manifestations and treatment considerations in COVID-19. Heart, 2020, 106(15): 1132-1141

[32] WongCK, LamCW, WuAK, et al.. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol, 2004, 136(1): 95-103

[33] PruijssersAJ, GeorgeAS, SchaferA, et al.. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep, 2020, 32(3): 107940

[34] AzevedoRB, BotelhoBG, HollandaJVG, et al.. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens, 2021, 35(1): 4-11

[35] HussainN, YoganathanA, HewageS, et al.. The effect of antivirals on COVID-19: a systematic review. Expert Rev Anti Infect Ther, 2021, 19(4): 473-486

[36] AgrawalU, RajuR, UdwadiaZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India, 2020, 76(4): 370-376

[37] FangQQ, HuangWJ, LiXY, et al.. Effectiveness of favipiravir (T-705) against wild-type and oseltamivir-resistant influenza B virus in mice. Virology, 2020, 545: 1-9

[38] ShirakiK, DaikokuT. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther, 2020, 209: 107512

[39] HossenMS, BarekMA, JahanN, et al.. A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN Compr Clin Med, 2020, 2(10): 1777-1789

[40] ElfikyAA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci, 2020, 253: 117592

[41] GuptaR, DhamijaP. Sofosbuvir for COVID-19 infection: A potential candidate. Indian J Pharmacol, 2020, 52(3): 232-233

[42] UzunovaK, FilipovaE, PavlovaV, et al.. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomed Pharmacother, 2020, 131: 110668

[43] WhiteNJ, WatsonJA, HoglundRM, et al.. COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. PLoS Med, 2020, 17(9): e1003252

[44] WangM, CaoR, ZhangL, et al.. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020, 30(3): 269-271

[45] SatarkerS, AhujaT, BanerjeeM, et al.. Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2. Curr Pharmacol Rep, 2020, 6(5): 203-211

[46] VankadariN. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents, 2020, 56(2): 105998

[47] LipworthBJ, ChanR, KuoCR. Tocilizumab for severe COVID-19 pneumonia. Lancet Rheumatol, 2020, 2(11): e660

[48] ZhangX, SongK, TongF, et al.. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv, 2020, 4(7): 1307-1310

[49] CalyL, DruceJD, CattonMG, et al.. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res, 2020, 178: 104787

[50] ZhangX, ZhangY, QiaoW, et al.. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharmacol, 2020, 86: 106749

[51] HuangC, WangY, LiX, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506

[52] ShyuD, DorrohJ, HoltmeyerC, et al.. Laboratory Tests for COVID-19: A Review of Peer-Reviewed Publications and Implications for Clinical Use. Mo Med, 2020, 117(3): 184-195

[53] JacofskyD, JacofskyEM, JacofskyM. Understanding Antibody Testing for COVID-19. J Arthroplasty, 2020, 35(7S): S74-S81

[54] DuttaNK, MazumdarK, GordyJT. The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development. J Virol, 2020, 94(13): e00647-20

[55] WallsAC, ParkYJ, TortoriciMA, et al.. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 2020, 181(2): 281-292.e6

[56] AugustineR, DasS, HasanA, et al.. Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World. J Clin Med, 2020, 9(10): 3372

[57] PrazuckT, ColinM, GiachèS, et al.. Evaluation of performance of two SARS-CoV-2 Rapid IgM-IgG combined antibody tests on capillary whole blood samples from the fingertip. PLoS One, 2020, 15(9): e0237694

[58] WeisslederR, LeeH, KoJ, et al.. COVID-19 diagnostics in context. Sci Transl Med, 2020, 12(546): eabc1931

[59] GeH, WangX, YuanX, et al.. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis, 2020, 39(6): 1011-1019

[60] ZhouM, ZhangX, QuJ. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med, 2020, 14(2): 126-135

[61] AhidjoBA, LoeMWC, NgYL, et al.. Current Perspective of Antiviral Strategies against COVID-19. ACS Infect Dis, 2020, 6(7): 1624-1634

[62] BauchnerH, FontanarosaPB. Randomized Clinical Trials and COVID-19: Managing Expectations. JAMA, 2020, 323(22): 2262-2263

[63] MalikS, GuptaA, ZhongX, et al.. Emerging Therapeutic Modalities against COVID-19. Pharmaceuticals (Basel), 2020, 13(8): 188

[64] Najjar-DebbinyR, GronichN, WeberG, et al.. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis, 2023, 76(3): e342-e349

[65] AgostiniML, AndresEL, SimsAC, et al.. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio, 2018, 9(2): e00221-18

[66] ChenJ, LinS, NiuC, et al.. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study. Expert Rev Respir Med, 2021, 15(2): 257-265

[67] PlantoneD, KoudriavtsevaT. Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. Clin Drug Investig, 2018, 38(8): 653-671

[68] DongL, HuS, GaoJ. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther, 2020, 14(1): 58-60

[69] HarrisonC. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol, 2020, 38(4): 379-381

[70] SpinnerCD, GottliebRL, CrinerGJ, et al.. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA, 2020, 324(11): 1048-1057

[71] ShirakiK, DaikokuT. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther, 2020, 209: 107512

[72] MagroG. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine X, 2020, 2(2): 100029

[73] TianX, LiC, HuangA, et al.. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect, 2020, 9(1): 382-385

[74] PuociF. “Monoclonal-Type” Plastic Antibodies for COVID-19 Treatment: What Is the Idea?. J Funct Biomater, 2020, 11(2): 43

[75] GrahamBS. Advances in antiviral vaccine development. Immunol Rev, 2013, 255(1): 230-242

[76] AfroughB, DowallS, HewsonR. Emerging viruses and current strategies for vaccine intervention. Clin Exp Immunol, 2019, 196(2): 157-166

[77] FidelPLJr, NoverrMC. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?. mBio, 2020, 11(3): e00907-20

[78] MadanM, PahujaS, MohanA, et al.. TB infection and BCG vaccination: are we protected from COVID-19?. Public Health, 2020, 185: 91-92

[79] AnkcornM, GallacherJ, IjazS, et al.. Convalescent plasma therapy for persistent hepatitis E virus infection. J Hepatol, 2019, 71(2): 434-438

[80] van GriensvenJ, EdwardsT, de LamballerieX, et al.. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med, 2016, 374(1): 33-42

[81] ShenC, WangZ, ZhaoF, et al.. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA, 2020, 323(16): 1582-1589

[82] RobackJD, GuarnerJ. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA, 2020, 323(16): 1561-1562